Sign In
Buy PTGX
$95.41
+2.18 (+2.34%)
At Close: Jun 03, 2026
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update
04:01pm, Wednesday, 10'th Mar 2021
NEWARK, Calif., March 10, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") (Nasdaq: PTGX) today reported financial results and provided a corporate update for the f
Will Protagonist Therapeutics (PTGX) Report Negative Q4 Earnings? What You Should Know
01:38pm, Tuesday, 02'nd Mar 2021
Protagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PTGX Stock Price Increases Over 15% Pre-Market: Why It Happened
08:41am, Tuesday, 02'nd Mar 2021
The stock price of Protagonist Therapeutics Inc (NASDAQ: PTGX) is trading at over 15% pre-market. This is why it happened.
Protagonist Therapeutics Reports Granting of Inducement Award
06:20pm, Friday, 26'th Feb 2021
NEWARK, Calif., Feb. 26, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today reported that on February 26, 2021, it issued an inducement award to Jami Taylor, the Company's recent
Protagonist Therapeutics Reports Granting of Inducement Award
06:22pm, Friday, 29'th Jan 2021
NEWARK, Calif., Jan. 29, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on January 29, 2021, it issued an inducement award to Paula O'Connor, M.D., the Company's
Protagonist (PTGX) Begins Dosing in Phase I Study With PN-235
10:32am, Thursday, 17'th Dec 2020
Protagonist Therapeutics (PTGX) doses the first patient in a phase I study on its oral IL-23 receptor antagonist, PN-235, being developed in collaboration with Janssen Biotech. Shares rise.
Protagonist Therapeutics Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Receptor Antagonist PN-235 (JNJ-77242113)
07:30am, Wednesday, 16'th Dec 2020
NEWARK, Calif., Dec. 16, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the first subject has been dosed in a Phase 1 study of PN-235 (also referenced as JNJ-77
Protagonist Therapeutics, Inc. Announces Pricing of $100 Million Public Offering of Common Stock
11:10pm, Thursday, 10'th Dec 2020
NEWARK, Calif., Dec. 10, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a clinical stage biopharmaceutical company, today announced the pricing of its previously announced underwr
Protagonist Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
07:30am, Thursday, 10'th Dec 2020
NEWARK, Calif., Dec. 10, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public of
NEWARK, Calif., Dec. 7, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced the results of a large-scale analysis of real world treatment patterns for polycythemia vera,
NEWARK, Calif., Dec. 6, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced additional updated results from the ongoing Phase 2 study of PTG-300 in patients with polycyth
Protagonist Therapeutics Reports Granting of Inducement Award
04:30pm, Tuesday, 01'st Dec 2020
NEWARK, Calif., Dec. 1, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on November 30, 2020, it issued an inducement award to Michelle Landolfi, Ph.D., the Compa
Protagonist Therapeutics to Participate in the Jefferies Virtual 2020 London Healthcare Conference
04:30pm, Wednesday, 11'th Nov 2020
NEWARK, Calif., Nov. 11, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fir
Protagonist Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update
04:54pm, Wednesday, 04'th Nov 2020
NEWARK, Calif., Nov. 4, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today reported its financial results for the third quarter ended September 30, 2020, and provided a corporate
NEWARK, Calif., Nov. 4, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced the acceptance of one oral and four poster presentations at the American Society for Hematolo
